Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors

Liu, Cunbao; Chu, Xiaojie; Yan, Ming; Qi, Jialong; Liu, Hongxian; Gao, Feng; Gao, Ruiyu; Ma, Guilei; Ma, Yanbing

doi:10.1016/j.ijpharm.2018.10.054

Cited by 32 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(b) Tumor size in a subcutaneous tumor model with the control of Poly I:C/CpG‐ODN incorporated into cationic lipid‐based nanoparticles. (Reprinted with permission from C. Liu, Chu, et al (). Copyright © 2018 Elsevier B.V.).…”

Section: Nanoparticle‐based Platforms For Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

100

View full text Add to dashboard Cite

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle‐based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. This review thus focuses on nanoparticle‐based platforms (especially naturally derived nanoparticles and synthetic nanoparticles) utilized in recent advances; summarizes delivery systems that incorporate various immune‐modulating agents, including peptides and nucleic acids, immune checkpoint inhibitors, and other small immunostimulating agents; and introduces combinational cancer immunotherapy with nanoparticles, especially nanoparticle‐based photo‐immunotherapy and nanoparticle‐based chemo‐immunotherapy. Undoubtedly, the recent studies introduced in this review prove that nanoparticle‐incorporated cancer immunotherapy is a highly promising treatment modality for patients with cancer. Nonetheless further research is needed to solve safety concerns and improve efficacy of nanoplatform‐based cancer immunotherapy for future clinical application. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Nanoparticle‐based Platforms For Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

100

View full text Add to dashboard Cite

show abstract

“…For the flow cytometry analysis of neutrophils, macrophages, NK cells, and T cells, cells were collected from lung BALF and washed with staining buffer. The flow cytometry protocol was performed as we previously reported 42 . Briefly, PE‐labeled antimouse Gr‐1 and APC‐labeled antimouse CD11b were used as markers for neutrophils; FITC‐labeled antimouse CD3 and APC‐labeled antimouse NK1.1 were used as markers for NK cells; and FITC‐labeled antimouse CD45, APC‐labeled antimouse CD8, and PE‐labeled antimouse CD4 were used as markers for CD8/CD4 cells.…”

Section: Methodsmentioning

confidence: 99%

Pulmonary Staphylococcus aureus infection regulates breast cancer cell metastasis via neutrophil extracellular traps (NETs) formation

Liu

et al. 2020

MedComm

View full text Add to dashboard Cite

The formation of neutrophil extracellular traps (NETs) was recently identified as one of the most important processes for the maintenance of host tissue homeostasis in bacterial infection. Meanwhile, pneumonia infection has a poor effect on cancer patients receiving immunotherapy. Whether pneumonia-mediated NETs increase lung metastasis remains unclear. In this study, we identified a critical role for multidrug-resistant Staphylococcus aureus infection-induced NETs in the regulation of cancer cell metastasis. Notably, S. aureus triggered autophagydependent NETs formation in vitro and in vivo and increased cancer cell metastasis. Targeting autophagy effectively regulated NETs formation, which contributed to the control of cancer metastasis in vivo. Moreover, the degradation of NETs by DNase I significantly suppresses metastasis in lung. Our work offers novel insight into the mechanisms of metastasis induced by bacterial pneumonia and provides a potential therapeutic strategy for pneumonia-related metastasis. K E Y W O R D S autophagy, cancer metastasis, multidrug-resistant (MDR) bacterial, neutrophil extracellular traps (NETs), pneumonia This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Thereby, encapsulation of the TLR3 adjuvant in a nanoparticle further potentiates the inflammatory immune responses ( 127 ). Especially when Poly (I:C) is combined with the TLR9 stimulant CpG in a nanoparticle, it induces protective and therapeutic immune responses in in vivo models ( 128 , 129 ). Other combinations of TLR ligands in nanoparticles are also used, with established synergistic effects ( 120 , 130 ).…”

Section: Battling Cancer With DC Targeted Liposome Vaccinesmentioning

confidence: 99%

Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance

Nagy

Haas²,

Geijtenbeek³

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Dendritic cells (DCs) are paramount in initiating and guiding immunity towards a state of activation or tolerance. This bidirectional capacity of DCs sets them at the center stage for treatment of cancer and autoimmune or allergic conditions. Accordingly, many clinical studies use ex vivo DC vaccination as a strategy to boost anti-tumor immunity or to suppress immunity by including vitamin D3, NF-κB inhibitors or retinoic acid to create tolerogenic DCs. As harvesting DCs from patients and differentiating these cells in vitro is a costly and cumbersome process, in vivo targeting of DCs has huge potential as nanoparticulate platforms equipped with activating or tolerogenic adjuvants can modulate DCs in their natural environment. There is a rapid expansion of the choices of nanoparticles and activation- or tolerance-promoting adjuvants for a therapeutic vaccine platform. In this review we highlight the most recent nanomedical approaches aimed at inducing immune activation or tolerance via targeting DCs, together with novel fundamental insights into the mechanisms inherent to fostering anti-tumor or tolerogenic immunity.

show abstract

Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors

Cited by 32 publications

References 43 publications

Nanotechnology platforms for cancer immunotherapy

Nanotechnology platforms for cancer immunotherapy

Pulmonary Staphylococcus aureus infection regulates breast cancer cell metastasis via neutrophil extracellular traps (NETs) formation

Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance

Contact Info

Product

Resources

About